Diagnosis of Severe Acute Respiratory Syndrome coronavirus 2, SARS-Cov-2, has spread into a world-wide pandemic at an unprecedented rate. Little is known concerning adverse events of a covid-19 diagnosis. With increased clotting factors, thrombotic events may be more likely. The interaction of SARS-Cov-2 and prescription birth control are unknown. However, hormonal birth control can cause thrombos is in high risk patients. (5) With the introduction of Covid-19 into this population, can we accurately determine an increase in thrombotic events? \n\nThrombotic events leading to pulmonary embolism have been reported in 31% of patients in an ICU with a Covid-19 diagnosis. (1) Patients entering the ICU with a Covid-19 diagnosis usually have comorbid conditions. The health of the population in an ICU differs from that of a non-hospitalized population. However, if thrombotic events are occurring at a higher rate in this population, pregnancy outcomes may be effected. Covid-19 infection increases systemic inflammation with high levels of C-Reactive protein and ferritin. (2) Inflammation in the body can lead to a clotting event; thus, the thrombotic events in women of reproductive age can jeopardize the viability of pregnancy. \n\nLimited data is available of Covid-19 as a causal effect of miscarriages. However, multiple letters to the editors have outlined suspicion of covid-19 infection contributing to miscarriage. Hachem et. al. found a late term miscarriage in a women who presented with vaginal bleeding and otherwise healthy pregnancy. The woman had a RT-PCR positive Covid-19 Result, and increased WBC levels and c- reactive protein. (3) Similarly, a first trimester miscarriage was reported in a woman who was diagnosed with Covid-19 at 10 weeks after substantial exposure. (4) \n\nKlok, F. A., Kruip, M. J. H. A., Van der Meer, N. J. M., Arbous, M. S., Gommers, D. A. M. P. J., Kant, K. M., … & Endeman, H. (2020). Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis research, 191, 145-147.\nBoggess, K. A., Lieff, S., Murtha, A. P., Moss, K., Jared, H., Beck, J., & Offenbacher, S. (2005). Maternal serum C-reactive protein concentration early in pregnancy and subsequent pregnancy loss. American journal of perinatology, 22(06), 299-304.\nHachem, R., Markou, G. A., Veluppillai, C., & Poncelet, C. (2020). Late miscarriage as a presenting manifestation of COVID-19. European Journal of Obstetrics and Gynecology and Reproductive Biology, 252, 614.\nWong, T. C., Lee, Z. Y., Sia, T. L., Chang, A. K., & Chua, H. H. (2020). Miscarriage risk in COVID-19 infection. SN Comprehensive Clinical Medicine, 2(9), 1449-1452.\nGray, B., Floyd, S., & James, A. H. (2018). Contraceptive management for women who are at high risk of thrombosis. Clinical obstetrics and gynecology, 61(2), 243-249